About us Contacts Drug interactions: 390 212
Drug search by name

Coumadin Injection and PCE Dispertab

Determining the interaction of Coumadin Injection and PCE Dispertab and the possibility of their joint administration.

Check result:
Coumadin Injection <> PCE Dispertab
Relevance: 09.11.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using warfarin together with erythromycin may cause you to bleed more easily. You may need a dose adjustment based on your prothrombin time or International Normalized Ratio (INR). Call your doctor promptly if you have any unusual bleeding or bruising, vomiting, blood in your urine or stools, headache, dizziness, or weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: Coadministration with clarithromycin or erythromycin may infrequently but substantially enhance the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism of interaction is unknown. Data from clinical studies have not supported a significant, predictable pharmacodynamic or pharmacokinetic interaction in general. Although both macrolides are potent inhibitors of CYP450 3A4 and can inhibit metabolism of the R(+) enantiomer of warfarin, the overall effect on racemic warfarin pharmacokinetics appears to be minor. In 12 normal subjects, the clearance of warfarin (1 mg/kg single dose) decreased by an average of 14% following pretreatment with erythromycin 250 mg four times a day for 8 days. In a study of eight patients stabilized on warfarin, the addition of erythromycin led to only a small increase in the effect of warfarin. Nevertheless, a population-based cohort study focusing on antibiotic use in outpatients treated with phenprocoumon or acenocoumarol at a Netherlands anticoagulant clinic identified clarithromycin use as a risk factor for overanticoagulation (INR greater than or equal to 6), even after adjustment for potential confounding factors. There have also been case reports of increased prothrombin time or INR and/or serious bleeding complications in patients stabilized on coumarin therapy following the addition of erythromycin or clarithromycin. The UK Committee on Safety of Medicines reported on a woman taking warfarin who suffered a fatal cerebrovascular bleed 3 days after starting clarithromycin. However, other influences such as fever, infection, malnutrition, and other concomitant underlying conditions on clotting mechanisms and coumarin pharmacokinetics should also be considered.

MANAGEMENT: Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones) and other similar macrolides (e.g., troleandomycin), although clinical data are lacking.

References
  • O'Donnell D "Antibiotic-induced potentiation of oral anticoagulant agents." Med J Aust 150 (1989): 163-4
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Hassell D, Utt JK "Suspected interaction: warfarin and erythromycin." South Med J 78 (1985): 1015-6
  • Grau E, Real E, Pastor E "Interaction between clarithromycin and oral anticoagulants." Ann Pharmacother 30 (1996): 1495-6
  • Gooderham MJ, Bolli P, Fernandez PG "Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin." Ann Pharmacother 33 (1999): 796-9
  • Schwartz J, Bachmann K, Perrigo E "Interaction between warfarin and erythromycin." South Med J 76 (1983): 91-3
  • Husserl FE "Erythromycin-warfarin interaction." Arch Intern Med 143 (1983): 1831, 1836
  • Kiran N, Azam S, Dhakam S "Clarithromycin induced digoxin toxicity: case report and review." J Pak Med Assoc 54 (2004): 440-1
  • Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy." Chest 126(3 Suppl) (2004): 204S-233S
  • Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. "Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants." Thromb Haemost 88 (2002): 705-10
  • Grau E, Fontcuberta J, Felez J "Erythromycin-oral anticoagulants interaction." Arch Intern Med 146 (1986): 1639
  • Loeliger EA, van der Esch B, Mattern MJ, Hemker HC "The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever." Thromb Diath Haemorrh 10 (1963): 267-77
  • Sato RI, Gray DR, Brown SE "Warfarin interaction with erythromycin." Arch Intern Med 144 (1984): 2413-4
  • Bachmann K, Schwartz JI, Forney R Jr, Frogameni A, Jauregui LE "The effect of erythromycin on the disposition kinetics of warfarin." Pharmacology 28 (1984): 171-6
  • Recker MW, Kier KL "Potential interaction between clarithromycin and warfarin." Ann Pharmacother 31 (1997): 996-8
  • Weibert RT, Lorentz SM, Townsend RJ, et al "Effect of erythromycin in patients receiving long-term warfarin therapy." Clin Pharm 8 (1989): 210-4
  • Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83
  • Bartle WR "Possible warfarin-erythromycin interaction." Arch Intern Med 140 (1980): 985-7
Coumadin Injection

Generic Name: warfarin

Brand name: Coumadin, Jantoven

Synonyms: Coumadin

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction